Skip to main content

Table 2 Baseline characteristics of BMF analysis and all-treated populations at entry into TED12037

From: Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis

Characteristic BMF analysis population (n = 21) All-treated population (n = 43)
Mean age, years (SD) 63.5 (10.7) 63.8 (10)
Sex, n (%)
 Male 12 (57) 26 (60)
 Female 9 (43) 17 (40)
Disease subtype, n (%)
 PMF 12 (57) 30 (70)
 Post-ET MF 1 (5) 2 (5)
 Post-PV MF 8 (38) 11 (26)
Risk status [27], n (%)
 High 8 (38) 15 (35)
 Intermediate 13 (62) 28 (65)
JAK2V617F mutation status, n (%)
 Positive 19 (90) 39 (91)
 Negative 2 (10) 4 (9)
Last fedratinib dose in TED12037, mg/day
 120 3 (14) 3 (7)
 240 2 (10) 4 (9)
 360 1 (5) 5 (12)
 400 0 1 (2)
 440 2 (10) 4 (9)
 520 7 (33) 11 (26)
 600 1 (5) 3 (7)
 680 5 (24) 12 (28)
BMF grade, n (%)
 0 0 (0) 0 (0)
 1 2 (10) 2 (5)
 2 10 (48) 10 (23)
 3 9 (43) 10 (23)a,b
Spleen size (cm), median (range) 18 (4–34) 18 (4–34)
Haemoglobin (g/dL), median (range) 9.7 (7.4–15.2) 9.3 (7.3–15.2)
White blood cells (×109/L), median (range) 16.4 (2.1–103.3) 14.9 (2.1–103.3)
  1. Percentages may not sum to 100 due to rounding
  2. aOne patient had a baseline BMF reading but no subsequent BMF readings and was therefore excluded from the BMF population
  3. bTwenty-one patients had missing baseline BMF data